Ergi Defne Güneş, Kahraman Ümit, Akkuş Gözde, Durmaz Seyfi, Balcıoğlu Özlem, Engin Çağatay, Yağmur Burcu, Nalbantgil Sanem, Çiçek Candan, Özbaran Mustafa, Yağdı Tahir
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, Bornova, 35100 Izmir, Turkey.
Department of Microbiology, Faculty of Medicine, Ege University, Bornova, 35100 Izmir, Turkey.
Diagnostics (Basel). 2023 Nov 16;13(22):3460. doi: 10.3390/diagnostics13223460.
We sought to investigate the impact of heart failure on anti-spike antibody positivity following SARS-CoV-2 vaccination. Our study included 103 heart failure (HF) patients, including those with and without left ventricular assist devices (LVAD) selected from our institutional transplant waiting list as well as 104 non-heart failure (NHF) patients who underwent open heart surgery at our institution from 2021 to 2022. All the patients received either heterologous or homologous doses of BNT162b2 and CoronaVac. The median age of the HF group was 56.0 (interquartile range (IQR): 48.0-62.5) and the NHF group was 63.0 (IQR: 56.0-70.2) years, and the majority were males in both groups ( = 78; 75.7% and = 80; 76.9%, respectively). The majority of the patients in both the HF and NHF groups received heterologous vaccinations ( = 43; 41.7% and = 52; 50.3%, respectively; = 0.002). There was no difference in the anti-spike antibody positivity between the patients with and without heart failure ( = 0.725). Vaccination with BNT162b2 led to significantly higher antibody levels compared to CoronaVac alone (OR: 11.0; 95% CI: 3.8-31.5). With each passing day after the last vaccine dose, there was a significant decrease in anti-spike antibody positivity, with an OR of 0.9 (95% CI: 0.9-0.9). Furthermore, hyperlipidemia was associated with increased antibody positivity ( = 0.004).
我们试图研究心力衰竭对SARS-CoV-2疫苗接种后抗刺突抗体阳性率的影响。我们的研究纳入了103例心力衰竭（HF）患者，包括从我们机构的移植等待名单中选取的有和没有左心室辅助装置（LVAD）的患者，以及2021年至2022年在我们机构接受心脏直视手术的104例非心力衰竭（NHF）患者。所有患者均接受了异源或同源剂量的BNT162b2和科兴疫苗。HF组的中位年龄为56.0岁（四分位间距（IQR）：48.0 - 62.5），NHF组为63.0岁（IQR：56.0 - 70.2），两组中大多数为男性（分别为78例；75.7%和80例；76.9%）。HF组和NHF组中的大多数患者接受了异源疫苗接种（分别为43例；41.7%和52例；50.3%；P = 0.002）。有心力衰竭和无心力衰竭患者之间的抗刺突抗体阳性率没有差异（P = 0.725）。与单独使用科兴疫苗相比，接种BNT162b2导致抗体水平显著更高（比值比：11.0；95%置信区间：3.8 - 31.5）。在最后一剂疫苗接种后的每一天，抗刺突抗体阳性率都有显著下降，比值比为0.9（95%置信区间：0.9 - 0.9）。此外，高脂血症与抗体阳性率增加相关（P = 0.004）。
